Polymorphism of platelet membrane glycoprotein IIIa: Human platelet antigen 1b (HPA-1b/PI(A2)) is an inherited risk factor for premature myocardial infarction in coronary artery disease

Thrombosis and Haemostasis

Volumn 79, Issue 4, 1998, Pages 731-735

  Zotz, Rainer B ^a   Winkelmann, Bernhard R ^b   Nauck, Markus ^c   Giers, Günther ^a   Maruhn Debowski, Beate ^a   März, Winfried ^c   Scharf, Rüdiger E ^a,d  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IIIA; THROMBOCYTE ANTIGEN;

ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; GENETIC RISK; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

EID: 0031978945     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615054     Document Type: Article

References (34)

1. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary artery disease. N Engl J Med 1986; 315: 983-9.
2. Lam JYT, Chesebro JH, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram. Quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol 1986; 8: 1380-6.
3. DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, Hinnen ML. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315: 417-23.
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
5. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-601.
6. Perutelli P, Mori PG. The human platelet membrane glycoprotein IIb/IIIa complex: a multi functional adhesion receptor. Haematologica 1992; 77: 162-8.
7. Nurden AT. Polymorphism of human platelet membrane glycoproteins: Structure and clinical significance. Thromb Haemost 1995; 74: 345-51.
8. Scharf RE. Molecular basis and clinical aspects of hereditary megakaryocyte and platelet membrane glycoprotein disorders. Haemostaseologie 1996; 16: 114-38.
9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
10. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-9.
11. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH. Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation 1991; 84: 708-11.
12. Verbeut FW, van der Laarse A, Funke-Kupper AJ, Sterkman LG, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 267-70.
13. The RISC Group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
14. Nyman I, Larsson H, Wallentin L. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischemia: the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Lancet 1992; 340: 497-501.
15. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorenson S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340; 1421-5.
16. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251-69.
17. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-9.
18. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-80.
19. 2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989; 21: 393-405.
20. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
21. Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley D, Worley SJ, Weisman HF, Califf RM, Topol EJ, for the EPIC investigators. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. J Am Coll Cardiol 1996; 28: 849-55.
22. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
23. Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992; 80: 1386-404.
24. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
25. Marian AJ, Brugada R, Kleiman NS. Platelet glycoprotein IIIa PLA polymorphism and myocardial infarction. (Letter) N Engl J Med 1996; 335: 1071-2.
26. Carter AM, Ossei-Gerning N, Grant PJ. Platelet glycoprotein IIIa PLA polymorphism and myocardial infarction. (Letter) N Engl J Med 1996; 335: 1072-3.
27. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
28. Osborn SV, Hampton KK, Smillie D, Channer KS, Daly ME. Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 1996; 348: 1309-10.
29. A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost 1997; 77: 1179-81.
30. Austen WG, Edwards JE, Frye RL, Gensini CG, Gott VL, Griffith LS. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51 (Suppl): 5-40.
31. Winkelmann BR, Nauck M, Klein B, Russ AP, Böhm BO, Siekmeier R, Ihnken K, Verho M, Groß W, März W. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med 1996; 125: 19-25.
32. Zotz RB, Giers G, Maruhn-Debowski B, Scharf RE. Genetic typing of human platelet antigen 1 (HPA-1) by oligonucleotide ligation assay in a specific and reliable semi-automated system. Brit J Haematol 1997; 96: 198-203.
33. Nurden AT. Polymorphisms of the platelet receptors as risk factors in coronary thrombosis. Eur Heart J 1996; 17: 1293-1294.
34. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996; 17: 9-18.